Document is current
Any future updates will be listed below
-
Authors
Swets, Maaike C. http://orcid.org/0000-0003-0901-9560
Kerr, Steven
Scott-Brown, James http://orcid.org/0000-0001-5642-8346
Brown, Adam B. http://orcid.org/0009-0002-1270-928X
Gupta, Rishi http://orcid.org/0000-0002-6257-1285
Millar, Jonathan E.
Spata, Enti
McCurrach, Fiona
Bretherick, Andrew D. http://orcid.org/0000-0001-9258-3140
Docherty, Annemarie http://orcid.org/0000-0001-8277-420X
Harrison, David
Rowan, Kathy http://orcid.org/0000-0001-8217-5602
Young, Neil
,
Groeneveld, Geert H.
Dunning, Jake
Nguyen-Van-Tam, Jonathan S. http://orcid.org/0000-0003-2579-4655
Openshaw, Peter http://orcid.org/0000-0002-7220-2555
Horby, Peter W. http://orcid.org/0000-0002-9822-1586
Harrison, Ewen http://orcid.org/0000-0002-5018-3066
Staplin, Natalie
Semple, Malcolm G. http://orcid.org/0000-0001-9700-0418
Lone, Nazir http://orcid.org/0000-0003-2707-2779
Baillie, J. Kenneth http://orcid.org/0000-0001-5258-793X
-
Funding
Funding for this research was provided by:
Wellcome Trust (223164/Z/21/Z)
RCUK | Medical Research Council (MC_PC_19025)
- License Information
-
More Information
Article History
Received: 23 May 2023
Accepted: 4 October 2023
First Online: 15 November 2023
Competing interests
: JKB and ABD report grants from the UK Department of Health and Social Care (DHSC), during the conduct of the study, and grants from Wellcome Trust,. PJMO reports personal fees from consultancies (GlaxoSmithKline, Janssen, Bavarian Nordic, Pfizer, and Cepheid) and from the European Respiratory Society, grants from MRC, MRC Global Challenge Research Fund, the EU, NIHR BRC, MRC–GlaxoSmithKline, Wellcome Trust, NIHR (HPRU in Respiratory Infection), and is an NIHR senior investigator outside the submitted work. PJMO’s role as President of the British Society for Immunology was unpaid but travel and accommodation at some meetings was provided by the Society. JKB reports grants from MRC. MGS reports grants from DHSC, NIHR UK, MRC, HPRU in Emerging and Zoonotic Infections, and University of Liverpool, during the conduct of the study, and is chair of the scientific advisory board and a minority shareholder at Integrum Scientific, outside the submitted work. JSN-V-T was seconded to the Department of Health and Social Care, England (DHSC), October 2017-March 2022. The views expressed in this manuscript are those of its authors and not necessarily those of DHSC. JSN-V-T reports personal fees and travel and accommodation from AstraZeneca. NS reports grants from Boehringer Ingleheim and Novo Nordisk outside the submitted work. The remaining authors declare no competing interests.
